[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital outcomes among inpatient admissions with a principal diagnosis of infective endocarditis.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of infective endocarditis\nInfective Endocarditis + Atrial Fibrillation Categories:\n\nInfective Endocarditis with Atrial Fibrillation\nInfective Endocarditis without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nAcute Renal Failure\nAcute Ischemic Stroke\nAcute Heart Failure\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital outcomes, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, and hospital region,\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, obstructive sleep apnea, anemia, obesity, alochol use disorder, and tobacco use disorder.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital outcomes among inpatient admissions with a principal diagnosis of infective endocarditis.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of infective endocarditis\nInfective Endocarditis + Atrial Fibrillation Categories:\n\nInfective Endocarditis with Atrial Fibrillation\nInfective Endocarditis without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nAcute Renal Failure\nAcute Ischemic Stroke\nAcute Heart Failure\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital outcomes, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, and hospital region,\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, obstructive sleep apnea, anemia, obesity, alochol use disorder, and tobacco use disorder.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 42,0751\nInfective Endcarditis without Atrial Fibrillation N = 34,7501\nInfective Endcarditis with Atrial Fibrillation N = 7,3251\np-value2\n\n\n\n\nAge, y\n51 (20)\n48 (19)\n67 (15)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n17,385 (41%)\n14,645 (42%)\n2,740 (37%)\n\n\n\n\n    Male\n24,690 (59%)\n20,105 (58%)\n4,585 (63%)\n\n\n\n\nRace\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n31,315 (77%)\n25,615 (76%)\n5,700 (81%)\n\n\n\n\n    Asian or Pacific Islander\n710 (1.7%)\n535 (1.6%)\n175 (2.5%)\n\n\n\n\n    Black\n4,340 (11%)\n3,740 (11%)\n600 (8.5%)\n\n\n\n\n    Hispanic\n3,175 (7.8%)\n2,740 (8.1%)\n435 (6.2%)\n\n\n\n\n    Native American\n390 (1.0%)\n360 (1.1%)\n30 (0.4%)\n\n\n\n\n    Other\n955 (2.3%)\n830 (2.5%)\n125 (1.8%)\n\n\n\n\nCharlson comorbidity index\n2.08 (2.17)\n1.84 (2.08)\n3.19 (2.24)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n13,525 (33%)\n11,535 (34%)\n1,990 (28%)\n\n\n\n\n    $52,000 - $65,999\n10,930 (27%)\n9,265 (28%)\n1,665 (23%)\n\n\n\n\n    $66,000 - $87,999\n9,175 (22%)\n7,290 (22%)\n1,885 (26%)\n\n\n\n\n    $88,000 or more\n7,230 (18%)\n5,570 (17%)\n1,660 (23%)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n12,120 (29%)\n10,505 (30%)\n1,615 (22%)\n\n\n\n\n    Medicaid\n14,185 (34%)\n13,415 (39%)\n770 (11%)\n\n\n\n\n    Medicare\n14,590 (35%)\n9,870 (28%)\n4,720 (64%)\n\n\n\n\n    Other\n1,135 (2.7%)\n915 (2.6%)\n220 (3.0%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n8,835 (21%)\n7,010 (20%)\n1,825 (25%)\n\n\n\n\n    Northeast\n9,340 (22%)\n7,745 (22%)\n1,595 (22%)\n\n\n\n\n    South\n16,375 (39%)\n13,840 (40%)\n2,535 (35%)\n\n\n\n\n    West\n7,525 (18%)\n6,155 (18%)\n1,370 (19%)\n\n\n\n\nHypertension\n20,640 (49%)\n15,035 (43%)\n5,605 (77%)\n&lt;0.001\n\n\nDiabetes mellitus\n9,155 (22%)\n6,585 (19%)\n2,570 (35%)\n&lt;0.001\n\n\nHyperlipidemia\n10,470 (25%)\n7,010 (20%)\n3,460 (47%)\n&lt;0.001\n\n\nCoronary artery disease\n7,670 (18%)\n4,910 (14%)\n2,760 (38%)\n&lt;0.001\n\n\nPeripheral vascular disease\n3,325 (7.9%)\n2,185 (6.3%)\n1,140 (16%)\n&lt;0.001\n\n\nHeart failure\n13,840 (33%)\n9,405 (27%)\n4,435 (61%)\n&lt;0.001\n\n\nChronic kidney disease\n8,435 (20%)\n5,975 (17%)\n2,460 (34%)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n7,360 (17%)\n5,615 (16%)\n1,745 (24%)\n&lt;0.001\n\n\nDementia\n1,300 (3.1%)\n870 (2.5%)\n430 (5.9%)\n&lt;0.001\n\n\nLiver disease\n6,545 (16%)\n5,810 (17%)\n735 (10%)\n&lt;0.001\n\n\nObstructive sleep apnea\n2,635 (6.3%)\n1,680 (4.8%)\n955 (13%)\n&lt;0.001\n\n\nAnemia\n4,780 (11%)\n3,990 (11%)\n790 (11%)\n0.4\n\n\nAlcohol use disorder\n12,640 (30%)\n10,315 (30%)\n2,325 (32%)\n0.14\n\n\nObesity\n5,025 (12%)\n3,725 (11%)\n1,300 (18%)\n&lt;0.001\n\n\nPrior stroke\n3,785 (9.0%)\n2,635 (7.6%)\n1,150 (16%)\n&lt;0.001\n\n\nPrior cardiac surgery\n5,115 (12%)\n3,485 (10%)\n1,630 (22%)\n&lt;0.001\n\n\nPacemaker/ICD\n2,250 (5.3%)\n1,260 (3.6%)\n990 (14%)\n&lt;0.001\n\n\nTobbacco use disorder\n545 (1.3%)\n515 (1.5%)\n30 (0.4%)\n0.001\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 42,0751\nInfective Endcarditis without Atrial Fibrillation N = 34,7501\nInfective Endcarditis with Atrial Fibrillation N = 7,3251\np-value2\n\n\n\n\nDied during hospitalization\n1,620 (3.9%)\n1,210 (3.5%)\n410 (5.6%)\n&lt;0.001\n\n\nLength of stay (days)\n12 (13)\n12 (13)\n13 (13)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n157,098 (248,192)\n149,393 (245,458)\n193,633 (257,734)\n&lt;0.001\n\n\nAcute renal failure\n10,285 (24%)\n7,780 (22%)\n2,505 (34%)\n&lt;0.001\n\n\nAcute ischemic stroke\n3,715 (8.8%)\n2,835 (8.2%)\n880 (12%)\n&lt;0.001\n\n\nAcute heart failure\n3,720 (8.8%)\n2,210 (6.4%)\n1,510 (21%)\n&lt;0.001\n\n\n\n1 n (%); Mean (SD)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n0.96\n0.70, 1.30\n0.8\n\n\nAge, y\n1.02\n1.01, 1.03\n0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.96\n0.75, 1.23\n0.8\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.53\n0.75, 3.10\n0.2\n\n\n    Black\n1.18\n0.82, 1.70\n0.4\n\n\n    Hispanic\n0.78\n0.45, 1.35\n0.4\n\n\n    Native American\n0.50\n0.07, 3.79\n0.5\n\n\n    Other\n1.77\n0.95, 3.32\n0.073\n\n\nCharlson comorbidity index\n1.19\n1.12, 1.27\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.83\n0.61, 1.13\n0.2\n\n\n    $66,000 - $87,999\n0.78\n0.56, 1.09\n0.15\n\n\n    $88,000 or more\n0.72\n0.48, 1.07\n0.10\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.82\n0.56, 1.20\n0.3\n\n\n    Medicare\n1.13\n0.78, 1.65\n0.5\n\n\n    Other\n2.18\n1.19, 4.01\n0.012\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.87\n0.59, 1.27\n0.5\n\n\n    South\n0.83\n0.60, 1.14\n0.2\n\n\n    West\n0.99\n0.68, 1.45\n&gt;0.9\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.81\n0.59, 1.12\n0.2\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.74\n0.53, 1.02\n0.065\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.61\n0.45, 0.84\n0.002\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.91\n0.66, 1.25\n0.5\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.08\n0.72, 1.61\n0.7\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.05\n1.54, 2.73\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.74, 1.44\n0.8\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.01\n0.75, 1.35\n&gt;0.9\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.84\n1.37, 2.47\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.48, 1.30\n0.4\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.49\n0.30, 0.82\n0.006\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.89\n0.68, 1.17\n0.4\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.80\n0.55, 1.15\n0.2\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.31, 3.41\n&gt;0.9\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nAcute Renal Failure:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n1.21\n1.04, 1.40\n0.012\n\n\nAge, y\n1.01\n1.01, 1.02\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.15\n1.03, 1.29\n0.012\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.55\n0.34, 0.86\n0.010\n\n\n    Black\n0.67\n0.55, 0.82\n&lt;0.001\n\n\n    Hispanic\n0.75\n0.60, 0.94\n0.011\n\n\n    Native American\n1.23\n0.67, 2.24\n0.5\n\n\n    Other\n1.15\n0.82, 1.61\n0.4\n\n\nCharlson comorbidity index\n1.08\n1.04, 1.12\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.94\n0.81, 1.08\n0.4\n\n\n    $66,000 - $87,999\n1.13\n0.97, 1.32\n0.11\n\n\n    $88,000 or more\n1.07\n0.90, 1.26\n0.5\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.21\n1.04, 1.41\n0.014\n\n\n    Medicare\n0.76\n0.64, 0.89\n0.001\n\n\n    Other\n1.19\n0.84, 1.70\n0.3\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.04\n0.88, 1.25\n0.6\n\n\n    South\n1.07\n0.93, 1.24\n0.3\n\n\n    West\n0.94\n0.78, 1.13\n0.5\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.16\n1.01, 1.34\n0.042\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.80, 1.09\n0.4\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.73\n0.63, 0.84\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.90\n0.77, 1.05\n0.2\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.63, 0.95\n0.014\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.83\n1.60, 2.08\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.28\n1.92, 2.71\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.85\n0.73, 0.98\n0.030\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.25\n1.07, 1.46\n0.004\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.20\n0.96, 1.48\n0.10\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.24\n1.05, 1.47\n0.011\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.87, 1.12\n0.9\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.27\n1.08, 1.50\n0.004\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.02\n0.60, 1.74\n&gt;0.9\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nAcute Ischemic Stroke:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n1.11\n0.88, 1.41\n0.4\n\n\nAge, y\n1.01\n1.00, 1.02\n0.005\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.12\n0.93, 1.34\n0.2\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.85\n0.42, 1.72\n0.6\n\n\n    Black\n0.97\n0.71, 1.33\n0.9\n\n\n    Hispanic\n1.03\n0.73, 1.46\n0.9\n\n\n    Native American\n1.08\n0.38, 3.06\n0.9\n\n\n    Other\n1.28\n0.76, 2.16\n0.4\n\n\nCharlson comorbidity index\n1.76\n1.66, 1.87\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.11\n0.88, 1.41\n0.4\n\n\n    $66,000 - $87,999\n1.00\n0.78, 1.29\n&gt;0.9\n\n\n    $88,000 or more\n1.07\n0.81, 1.41\n0.6\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.72\n0.56, 0.94\n0.017\n\n\n    Medicare\n0.80\n0.61, 1.03\n0.083\n\n\n    Other\n0.84\n0.48, 1.49\n0.6\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.93\n0.69, 1.26\n0.6\n\n\n    South\n0.98\n0.76, 1.26\n0.9\n\n\n    West\n1.04\n0.77, 1.40\n0.8\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.09\n0.86, 1.39\n0.5\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.48\n0.37, 0.62\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.95\n0.75, 1.22\n0.7\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.94\n0.73, 1.20\n0.6\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.43\n0.30, 0.61\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.52\n0.42, 0.65\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.21\n0.16, 0.28\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.47\n0.37, 0.61\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.41\n0.30, 0.55\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.92\n0.63, 1.32\n0.6\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.86\n0.64, 1.17\n0.3\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.00\n0.81, 1.23\n&gt;0.9\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.25\n0.96, 1.61\n0.10\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.08\n0.48, 2.44\n0.9\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nAcute Heart Failure:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n1.08\n0.87, 1.35\n0.5\n\n\nAge, y\n1.03\n1.02, 1.04\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.12\n0.90, 1.39\n0.3\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.85\n0.41, 1.73\n0.6\n\n\n    Black\n0.41\n0.29, 0.59\n&lt;0.001\n\n\n    Hispanic\n0.60\n0.38, 0.93\n0.022\n\n\n    Native American\n1.20\n0.52, 2.77\n0.7\n\n\n    Other\n0.67\n0.33, 1.36\n0.3\n\n\nCharlson comorbidity index\n1.04\n0.97, 1.12\n0.3\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.93\n0.70, 1.24\n0.6\n\n\n    $66,000 - $87,999\n0.99\n0.75, 1.32\n&gt;0.9\n\n\n    $88,000 or more\n1.08\n0.77, 1.50\n0.7\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.88\n0.61, 1.28\n0.5\n\n\n    Medicare\n0.67\n0.49, 0.91\n0.010\n\n\n    Other\n0.79\n0.36, 1.73\n0.6\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.86\n0.60, 1.22\n0.4\n\n\n    South\n1.11\n0.85, 1.45\n0.4\n\n\n    West\n0.89\n0.64, 1.25\n0.5\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n10.5\n6.51, 16.8\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.91\n0.70, 1.18\n0.5\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.75\n0.60, 0.94\n0.014\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.37\n1.10, 1.71\n0.005\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.61\n1.19, 2.18\n0.002\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n43.5\n27.2, 69.7\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n10.2\n7.60, 13.6\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.01\n0.79, 1.29\n&gt;0.9\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.01\n0.71, 1.43\n&gt;0.9\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.28\n0.94, 1.75\n0.12\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.73, 1.34\n&gt;0.9\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.00\n0.79, 1.26\n&gt;0.9\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.95\n0.73, 1.23\n0.7\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.75\n0.13, 4.28\n0.7\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Impact of Atrial Fibrillation on In-Hospital Outcomes in Infective Endocarditis Patients",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n2.4\n1.6, 3.3\n&lt;0.001\n\n\nAge, y\n-0.07\n-0.10, -0.05\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n-0.23\n-0.84, 0.38\n0.5\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.7\n-0.35, 3.8\n0.10\n\n\n    Black\n0.63\n-0.46, 1.7\n0.3\n\n\n    Hispanic\n0.06\n-1.0, 1.1\n&gt;0.9\n\n\n    Native American\n0.66\n-2.2, 3.5\n0.6\n\n\n    Other\n4.0\n0.05, 7.9\n0.047\n\n\nCharlson comorbidity index\n0.64\n0.43, 0.85\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.01\n-0.78, 0.79\n&gt;0.9\n\n\n    $66,000 - $87,999\n0.05\n-0.75, 0.85\n&gt;0.9\n\n\n    $88,000 or more\n-0.89\n-1.7, -0.02\n0.044\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.78\n-0.05, 1.6\n0.066\n\n\n    Medicare\n-0.39\n-1.3, 0.50\n0.4\n\n\n    Other\n-0.70\n-2.4, 1.0\n0.4\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.1\n0.08, 2.1\n0.034\n\n\n    South\n2.2\n1.3, 3.1\n&lt;0.001\n\n\n    West\n0.16\n-0.86, 1.2\n0.8\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.41\n-0.32, 1.1\n0.3\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.43\n-1.2, 0.38\n0.3\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.9\n-2.6, -1.3\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.31\n-1.0, 0.38\n0.4\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.0\n-2.4, 0.35\n0.14\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.4\n1.6, 3.1\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.37\n-1.4, 0.66\n0.5\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.63\n-1.4, 0.14\n0.11\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.7\n0.76, 2.6\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.75\n-1.6, 0.13\n0.10\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.8\n0.94, 2.6\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.29\n-0.46, 1.0\n0.5\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.23\n-0.53, 0.98\n0.6\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.9\n-4.2, 0.30\n0.090\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n\n\n    Infective Endcarditis without Atrial Fibrillation\n—\n—\n\n\n\n\n    Infective Endcarditis with Atrial Fibrillation\n37,353\n20,165, 54,541\n&lt;0.001\n\n\nAge, y\n-1,373\n-1,861, -884\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n2,810\n-8,163, 13,782\n0.6\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n27,855\n-20,174, 75,884\n0.3\n\n\n    Black\n33,250\n13,196, 53,303\n0.001\n\n\n    Hispanic\n26,157\n491, 51,823\n0.046\n\n\n    Native American\n-31,544\n-68,364, 5,276\n0.093\n\n\n    Other\n104,726\n26,677, 182,775\n0.009\n\n\nCharlson comorbidity index\n12,097\n7,721, 16,473\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n311\n-13,445, 14,068\n&gt;0.9\n\n\n    $66,000 - $87,999\n6,452\n-9,163, 22,068\n0.4\n\n\n    $88,000 or more\n-310\n-17,173, 16,553\n&gt;0.9\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n-28,429\n-42,816, -14,041\n&lt;0.001\n\n\n    Medicare\n-14,503\n-31,532, 2,526\n0.10\n\n\n    Other\n-137\n-31,880, 31,607\n&gt;0.9\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n37,654\n15,746, 59,563\n&lt;0.001\n\n\n    South\n9,079\n-6,307, 24,465\n0.2\n\n\n    West\n69,631\n46,692, 92,569\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n12,669\n-1,188, 26,525\n0.073\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-10,778\n-26,014, 4,459\n0.2\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-26,177\n-39,979, -12,376\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n12,274\n-3,607, 28,156\n0.13\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-13,248\n-40,901, 14,404\n0.3\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n76,403\n59,862, 92,944\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-21,111\n-41,717, -506\n0.045\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-21,250\n-35,144, -7,355\n0.003\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n22,352\n4,074, 40,629\n0.017\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-9,592\n-29,260, 10,076\n0.3\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n6,626\n-7,765, 21,018\n0.4\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n9,299\n-4,879, 23,477\n0.2\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n13,193\n-2,328, 28,713\n0.10\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-7,277\n-51,718, 37,164\n0.7\n\n\n\n1 CI = Confidence Interval"
  }
]